BOARD OF DIRECTORS
Between 1983 and 1997 he held a number of positions:
(i) Commercial agent at Petrini S.p.A. (1982-1983);
(ii) Director at the agro-business Valentina Nuova (1984-1986);
(iii) Product Manager at Petrini S.p.A., with a particular focus on nutrition (1986-1988);
(iv) Commercial Director and, subsequently, General Manager of S.I.M.B. S.r.l.. (1988-1997).
He has been the Chairman – while is also the founder – since 1997 of Nutristar S.p.A.
Andrea Lacorte, after carrying out extensive research in the fields of nutrition and human lipidology, in addition contributed to the foundation of (i) Alesco S.r.l. (in 2000), holding the position of Vice Chairman of the Board of Directors until now and (ii) Pharmanutra S.p.A. (in 2003), acting until now as Chairman.
Since 2011, he has been Vice Chairman of the Board of Directors of Junia Pharma. Andrea Lacorte has carried out research and created sucrosomial solutions with human application.
Between January 1995 and April 1996, he carried out military service with the Marines.
Between February 1996 and April 1997, he was employed at the Giovanni Bucarelli commercial firm in Pisa, specialising in accounting and administrative matters.
Subsequently, Roberto Lacorte was hired by the Claudio Bucchianica Accountancy Firm in Pisa, with involvement in bankruptcies and corporate and administrative operations (1997-2000).
Since 2002, he has been a partner at the Bucarelli Lacorte Cognetti Accountancy Firm.
Roberto Lacorte was a director at Lira s.a.s. between 1998 and 2001.
He holds in addition the following positions: Director at Nutristar S.r.l. (since 2000); Director at Alesco S.r.l. (since 2001); Vice Chairman of the Board of Directors of Pharmanutra (since 2003); Chairman of the Board of Directors of Junia Pharma (since 2009).
Since 2002, he has been involved in start-ups with a particular
focus on the shipbuilding sector.
Since November 2005, Roberto Lacorte has taught at the FUCINA institute (training institute of the nautical sector industrial association); owner of the “Management di bordo (on-board management)” course.
He is enrolled to the list of Accountants and Auditors.
In 1984, he was appointed as Parmalat Authorised Retailer Automation Manager at Sisted.
Between 1986 and 1993, he was a Financial Analyst at Banca Monte Parma.
Between 1993 and 2000, he held a number of roles at the PAM Group: Assistant to the Chief Executive Officer (1993-1994); Lazio Area Supermarkets Manager (1995-1997); Supermarkets Marketing Manager (1997-1998); Superstore Business Unit Manager (1998-1999); Hypermarkets Regional Manager (1999-2000).
From 2000 to 2002 he worked as Management Consultant for the McKinsey&Co.
Between 2003 and 2006, he was the Ethics Business Unit Manager at Schering Italia. During the 2006-2008 two-year period, he was the Chief Executive Officer of Step S.p.A.. Also in this period, he was an Oversight Director at Management & Capitali S.p.A.. Between 2008 and 2015, he was the Chief Executive Officer of Vertigo S.r.l.. In 2013, he founded Beda S.r.l., of which he is a shareholder and sole director.
Since 2009, he has been a Director and the Chief Marketing Officer of Pharmanutra spa.
He also holds the position as Member of the Board of Directors in all the three companies: Pharmanutra Spa, Junia Pharma Srl and Alesco Srl.
In 2014 he became a member of Junia Pharma Board of Directors.
Germano Tarantino manages all the research activities of Pharmanutra S.p.a, focalising the attention on sucrosomial technology for the development of nutraceutical supplements with human application and medical devices.
Moreover, from his own researches, he has created several patents.
Since 1996 he has been listed on the Register of Chartered Accountants and Tax Consultants for the Pisa Court District and on the Register of Auditors since 1999.
In 1996 he also entered in the Register of Technical Consultants to the Court in the Civil Section for Commercial and Tax Matters. He started his professional career in 1996 and established his own firm.
Later on he co-founded the Bucarelli Lacorte Cognetti Accountancy Firm in 2002. Currently he is a Statutory Auditor Nutristar S.p.A., a company based in Reggio Emilia.
He has been collaborating with Pharmanutra S.p.A. as administrative and fiscal consultant since its establishment.
Moreover since May 2019 he holds the position as member of the Board of Directors for Pharmanutra Spa.
Since 1987 he is in the register of Chartered accountant and skilled professional in the field of the city of Bologna, since 1995 he is recorded under the Legal Auditor Register at MEF and at CTU of Bologna Court.
Since 1989, he has been a Receiver and Court appointed Administrator at the Bologna Court and recently he has been nominated Crisis Supervisor from the Crisis Composition Organisation at the Bologna ODEC.
Moreover since 1995, he has acted as a Technical Consultant for the Bologna Public Prosecutors Office.
Since 2005, he has held the position as Advisor in favour of different enterprises concerning recovery plans, debt restorations, composition with creditors, and assistance in special corporate operations.
In 1998 he was appointed the Liquidator of Derbito S.p.A. and in 2006 the Liquidator of S.A.G.I.S. S.p.A.
He currently holds positions at a number of companies: Chairman of the Board of Statutory Auditors of F.A.A.C. S.p.A and of the FAAC Holding industry participation S.r.l; Chairman of the Board of Statutory Auditors of Oblique Creations S.r.l;
Chairman of the Board of Statutory Auditors of Firbimatic S.p.A.; Statutory Auditor of Union S.p.A.; Chairman of the Board of Statutory Auditors of Nutristar S.r.l.; Chairman of the Board of Statutory Auditors of Piccinini S.p.A.; Statutory Auditor of Espansione Marketing S.p.A.; Statutory Auditor of Realstar S.r.l.; Statutory Auditor of Hub Italia S.r.l;
Director of Iredeem S.p.A and Sole Director of Bima Consulting S.r.l..
Chairman of Genus, the promoter of SPAC Made in Italy 1, of which he was the Chief Executive Officer until the business combination with SeSa, one of the main IT active company in Italy listed in STAR;
Chairman of IPO Challenger, an innovative Prebooking Company which listed Italian Wine Brands, the first wine group competed in the stock market of which he is actually the Vice President.
In 2017 he established a partnership between Electa- Ventures and Azimut Group with which he found the IPO club, focused on IPO acceleration, in spac feeder investor activities and prebooking company dedicated to excellent PMI.
In March 2017 he launched Ipo Challenger 1, a quick cycle prebooking company, which listed Pharmanutra spa.
In 2018 he coordinated the Digital Value professional development with the first application of the innovative format “spac in cloud”.
He currently holds positions as Member of the Board of Directors for Pharmanutra Spa and Digital Value Spa, Giordano Vini Spa and Provinco Spa.
He still has the role of the Chairman of AISPAC – Italian Association for the promotion of SPAC’s and Prebooking companies- and in addition he is the Chairman of the Consultative Committee of the IPO CLUB fund.
BOARD OF STATUTORY AUDITORS
He is a Statutory Auditor in various companies and is registered with the Register of Chartered Accountants, Auditors, Certified Practitioners of the Bar Association and Public Journalists. He is Chairman of the Tax Commission of the Chamber of Chartered Accountants of Parma, Member of the Tax Committee of ANDAF and lecturer at AIFO. He participates as a speaker at numerous national and international conferences and workshops and is the author of numerous publications in the tax field. Andrea has a degree in Economics and Commerce, in Law and an MBA from SDA Bocconi.
BDO Italia S.p.A.
Registered office in Milan, Viale Abruzzi n. 94,
Registered in the special register of auditing companies pursuant to D. Lgs. n. 39/2010
Corporate Family Office SIM S.p.A.
Registered office in Milan
Via dell’Annunciata n. 23/4
TERMINI E CONDIZIONI
Per poter accedere al presente sito web ed al documento di ammissione è necessario leggere e accettare l’informativa di seguito riportata che il lettore deve valutare attentamente prima di leggere, accedere o utilizzare in qualsiasi altra maniera le informazioni di seguito fornite. Accedendo al presente sito web, si accetta di essere soggetti ai termini e alle condizioni di seguito riportati, e a qualsivoglia successivo aggiornamento degli stessi.
Il Documento di Ammissione riportato nella presente sezione del sito web (il “Documento di Ammissione”) è un Documento di Ammissione sull’AIM Italia – Mercato Alternativo del Capitale, sistema multilaterale di negoziazione organizzato e gestito da Borsa Italiana S.p.A., delle azioni (le “Azioni”) e dei warrant (“Warrant”) di Pharmanutra S.p.A. (la “Società”) ed è stato redatto ai sensi del regolamento emittenti AIM Italia (“Regolamento Emittenti Aim Italia”). Il Documento di Ammissione e l’operazione descritta nel medesimo non costituiscono un’offerta al pubblico di strumenti finanziari né un’ammissione di strumenti finanziari in un mercato regolamentato così come definiti dal Testo Unico della Finanza, dal Regolamento Consob n. 11971 del 14 maggio 1999, come successivamente modificato ed integrato, e dalle equivalenti disposizioni di legge e regolamentari applicabili all’estero.
Le seguenti informazioni ed il Documento di Ammissione sono accessibili soltanto a soggetti che: (a) sono residenti in Italia e che non sono domiciliati né comunque si trovano attualmente negli Stati Uniti d’America, Australia, Giappone, Canada nonché in qualsiasi altro Paese in cui la diffusione del Documento di Ammissione e/o di tali informazioni richieda l’approvazione delle competenti Autorità locali o sia in violazione di norme o regolamenti locali (“Altri Paesi”) e (b) non sono “U.S. Person” secondo la definizione contenuta nella Regulation S dello United States Securities Act del 1933, come successivamente modificato, né sono soggetti che agiscono per loro conto o a loro beneficio senza l’esistenza di un’apposita registrazione o di una specifica esenzione alla registrazione prevista ai sensi dello United States Securities Act e della normativa vigente.
Alla “U.S. Person” nel senso sopra indicato è preclusa la possibilità di accesso e di download del documento di ammissione attraverso questo sito web. Per nessuna ragione e in nessuna circostanza è consentito far circolare, direttamente o tramite terzi, il Documento di Ammissione e ogni altra informazione contenuta nella presente sezione del sito web al di fuori dell’Italia, in particolare negli Stati Uniti, in Australia, in Giappone, in Canada o negli Altri Paesi, né è consentito distribuire il Documento di Ammissione a una “U.S. Person” nel senso sopra indicato. L’inosservanza di tale disposizione può comportare una violazione dello United States Securities Act o della normativa applicabile in altre giurisdizioni.
Le informazioni contenute in questo sito web (o in qualsiasi altro sito col quale il presente sito web abbia collegamenti ipertestuali) non costituiscono offerta, invito ad offrire o attività promozionale in relazione alle azioni nei confronti di alcun cittadino o soggetto residente in Canada, Australia, Giappone o negli Stati Uniti d’America o in qualsiasi altro Paese nel quale tali atti non siano consentiti in assenza di specifiche esenzioni o autorizzazioni da parte delle competenti autorità. Le azioni e le obbligazioni convetibili non sono né saranno oggetto di registrazione ai sensi dello United States Securities Act del 1933, così come modificato o presso alcuna autorità regolamentare di qualsiasi stato o altra giurisdizione degli stati uniti d’America e non potranno essere offerte o vendute negli Stati Uniti d’America o a, o per conto o a beneficio di, una U.S. Person, nel senso sopra indicato, in assenza di tale registrazione o di espressa esenzione da tale adempimento o in altri Paesi in cui l’offerta di azioni sia soggetta a limitazioni in base alla normativa vigente.
Per accedere al presente sito web, al Documento di Ammissione e ad ogni altra informazione contenuta nelle seguenti pagine, dichiaro sotto la mia piena responsabilità di essere residente in Italia e di non essere domiciliato né di trovarmi attualmente negli Stati Uniti d’America, in Australia, Giappone, in Canada o negli Altri Paesi e di non essere una “U.S. Person” come definita nella Regulation S dello United States Securities Act del 1933, come successivamente modificato. Confermo di aver letto e di accettare i termini e le condizioni di cui sopra.
SHARES STUDY AND RESEARCH
SHARE CAPITAL AND SHAREHOLDERS
The share capital of Pharmanutra S.p.A. amounts to Euro 1.123.097,70, comprising 9.680.977 ordinary shares without nominal value.
The Ordinary Shares of Pharmanutra S.p.A. have been admitted to trading on the AIM Italia/Alternative Capital Market.
The following table presents, according to the shareholders’ register, in addition to other information available to Pharmanutra S.p.A., the shareholders which hold at least 5% of the share capital.
|Direct shareholder||Number of shares||Percentage of share capital with voting rights|
|Andrea Lacorte||3.118.334 (1)||32,21%|
|Roberto Lacorte||2.318.833 (2)||23,95%|
|Beda S.r.l. (3)||1.094.993||11,31%|
|Kairos Partners SGR S.p.A.||499.259||5,16%|
(1) Of which 953.334 PHN ordinary shares are held through the trust company COFIRCONT Compagnia Fiduciaria S.r.l pursuant to a specific fiduciary mandate.
(2) Of which 953.333 PHN ordinary shares are held through the trust company COFIRCONT Compagnia Fiduciaria S.r.l pursuant to a specific fiduciary mandate.
(3) It should be noted that Carlo Volpi is sole shareholder and sole director of Beda S.r.l.
SIGNIFICANT SHAREHOLDER DISCLOSURE OBLIGATIONS
In accordance with the By-Laws and the AIM Italia/Alternative Capital Market Issuers’ Regulation, those who hold a number of financial instruments of Pharmanutra S.p.A. admitted for trading to the AIM Italia/Alternative Capital Market equal to or exceeding the threshold established in accordance with the AIM Italia/Alternative Capital Market Issuers’ Regulation, are required to communicate such in a timely manner to the Board of Directors of Pharmanutra S.p.A. through registered fax to the number +39.02.7214231.
In particular, in accordance with the By-Laws and the AIM Italia/Alternative Capital Market Issuers’ Regulation, this communication is required on the reaching or surpassing of the 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 66.6%, 75%, 90% and 95% thresholds of the share capital with voting rights of Pharmanutra S.p.A., in addition to reductions below the above-stated thresholds (the “Significant Investment”).
The reaching or surpassing of the Significant Investment is considered a “Substantial change” which should be communicated by Shareholders to Pharmanutra S.p.A. within 5 (five) trading days from the occurrence of the act or event giving rise to the obligation, independently of the execution date, according to the terms and means established by the Transparency Regulation.
The communication of the “Substantial change” should identify the shareholder, the type and the amount of the investment; the date on which the shareholder acquired or disposed of the share capital percentage resulting in a “Substantial change”, or the date on which the percentage of their investment increased or reduced above/below the thresholds established by the AIM Italia/Alternative Capital Market Issuers’ Regulation.
For such purposes, shareholders are invited to use the communication forms and the relative instructions at Annex 4 (Ownership structure) of the Regulation issued by Consob with motion No. 11971 of 1999, with the understanding that references to the regulated markets or to listed companies should be considered as references to multilateral trading systems.
In accordance with Article 8 of the By-Laws, failure to communicate to the Board of Directors a “Substantial change” results in the suspension of voting rights for the shares or financial instruments to which such communication failure relates.
23rd March 2019 Board of Directors’ meeting to approve the Pharmanutra S.p.A. draft financial statements at 31ˢᵗ December 2019.
27th – 28th April 2019 Shareholders’ Meeting to approve the Pharmanutra S.p.A. draft financial statements at 31ˢᵗ December 2019 scheduled for 27ᵗʰ and 28ᵗʰ April 2019, first and second call respectively.
14th September 2019 Board of Directors’ meeting to approve the Pharmanutra S.p.A. half-yearly financial report at 30ᵗʰ June 2020.
COMMUNICATION OF REGULATED INFORMATION
Pharmanutra S.p.A. indicates that for the sending and storage of Regulated Information, use is made of the eMarket SDIR circulation system and the eMarket STORAGE mechanism managed by Spafid Connect S.p.A., with registered office in Foro Buonaparte 10, Milan.
- 20/07/2020 - PHARMANUTRA CELEBRATES THREE YEARS SINCE BEING LISTED ON THE AIM ITALIA MARKET
- 14/07/2020 - PHARMANUTRA S.P.A.: REVENUE INCREASES +17% IN THE FIRST HALF OF 2020
- 17/06/2020 - (ITALIANO) PHARMANUTRA S.P.A.: COMUNICAZIONE AI SENSI DELL’ART. 17 DEL REGOLAMENTO EMITTENTI AIM ITALIA
- 12/06/2020 - AGREEMENT RELATED TO THE PATENT BOX REGIME SIGNED WITH THE REVENUE OFFICE